FORM PTO-1449 US Dept. of Commerce			ATTORNEY DOCKET NO.		SERIAL NO.		
Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT		_	014835.77.02-034				
			Redfield, et al.				
			FILING DATE		GROUP		
		IIS I	07-07-2005 PATENT DOCUMENTS		1617		
EXAMINE R INITIAL	PATENT or APPLICATION NUMBER	ISSUE OR PUBLICATION DATE	NAME	CLASS	SUBCLASS		ING DATE PROPRIATE
/K.C./	6096780	08-01-2000	Shiraishi et al.				
/K.C./	6,013,644	1/11/2000	Mills, et al.				
/K.C./	5,962,462	10/5/1999	Mills, et al.				
/K.C./	6,150,530	11/21/2000	Kempf, et al.				
/K.C./	5,994,136	11/30/1999	Naldini				
/K.C./	20030099944	5/29/2003	Schaffer et al.				
/K.C./	20030060457	3/27/2003	Schaffer et al.				
-	DOCUMENT	PUBLICATION	NAME OF PATENTEE OR		1	тра	NSLATION
	DOCUMENT	TOBLICATION	APPLICANT OF CITED DOCUMENT			IKA	NSLATION
	NUMBER	DATE	DOCUMENT	CLASS	SUBCLASS	YES	NO
/K.C./	WO 99/48504	09-30-1999	Lisziwiewicz, at al.				
/K.C./	WO 99/47146	09-23-1999	Lisziwiewicz, at al.				
/K.C./	WO 02/053096	11 July 2002	Schaffer				
/K.C./	WO 02/062123	15 August 2002	Anderson				
/K.C./	WO98/25604	12/12/1997	Merck				
/K.C./	WO00/51610	3/1/2000	Merck				
/K.C./	WO02100401	6/5/2002	Schering				
/K.C./	WO03/027671	9/25/2002	Eirx				
/13.57.	OTHER DOCU	MENTS (Includi	ing Author, Title, Journal-D	ate, Page N	umber, Etc.)	)	
/K.C./	ANDRIEU, et al. "Results of a 2-year exploratory study with cyclosporin a in human immunodeficiency virus infection." (1998) in <i>Autoimmune Aspects of HIV Infection</i> , eds. (R. Soc.						
/K.C./	Med. Services, London), pp. 191-194.  Paton, et al., "Hydroxychloroquine, hydroxycarbamide and didanosine as economic treatment for						
/K.C./	HIV-1" The Lancet, (2002) V.359, 1667  Spada, et al. "An Evaluation of Antiretrovial Therapy Associated with α-Tocopherol" Clin.						
7.000//		Ied (2002) 40(5)		Foy I C	shoelz D. V	an I tal	narman D
/K.C./	Johnson, R., M	Calabrese, L., Lederman, M., Spritzler, J., Coombs, R., Fox, L., Schock, B., Yen-Lieberman, B., Johnson, R., Mildvan, D. & Parekh, N. (2002) <i>J. Acquired Immune Defic. Syndr.</i> 29, 356-362.					56-362.
/K.C./		Lori, et al. "Strucutured treatment interruptions as a potential alternative therapeutic regimen", Journal of Antimicrobial Chaemotherapy (2002) 50, 155-160.					e regimen",
EXAMINER	J. WILLIAM OI THE				ONSIDERED	ı	
			not citation is in conformance		-		_
citation if not in	conformance and no	t considered. Incl	lude copy of this form with nex	xt communi	cation to the a	pplican	<u>t.</u>

ORM PTO-14	49 US Dept. of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO. <b>014835.77.02-034</b>	SERIAL NO. 10/527,904			
IST OF DOCU	MENTS CITED BY APPLICANT	APPLICANT Redfield, et al.				
		FILING DATE 07-07-2005	GROUP 1617			
/K.C./	<i>Retroviruses</i> 15, 647-653.	scherning, C., Albert, J. & Feny				
/K.C./	Loetscher, P., Seitz, M., Baggiolini, M. & Moser, B. (1996) J. Exp. Med. 184, 569-577.					
/K.C./	Morice, et al. (1993) J. Biological Chemistry, Vol 268 (5) pp. 3734-3738.					
/K.C./	Poon, M., Badimon, J. & Fuster, V. (2002) Lancet 359, 619-622.					
/K.C./	Castedo, et al., (2002) EMBO Journal, 21 (15) pp. 4070-4080.					
/K.C./	Reeves J et al., (2002) PNAS 99: 16249-16254.					
/K.C./	Rizzardi, G., Harari, A., Capiluppi, B., Tambussi, G., Ellefsen, K., Ciuffreda, D., Champagne, P., Bart, P., Chave, J., Lazzarin, A. & Pantaleo, G. (2002) <i>Clin. Invest.</i> 109, 681-688.					
/K.C./	Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) Nat. Med. 8, 128-135.					
/K.C./	Heredia, A; Amoroso, A; Davis, C.; Le, N.; Readon, E.; Klingebiel, E.; Gallo, R.C; and Redfield R.R. (2003) <i>Proc. Natl. Acad. Sci. USA</i> , 100 (18) 10411-10416.					
/K.C./	Heredia, A., Davis, C., Amoroso, A., Dominique, J., Le, N., Klingebiel, E., Reardon, E., Zella, D & Redfield, R. (2003) <i>Proc. Natl. Acad. Sci. USA</i> 100, 4179-4184.					
/K.C./	Heredia, A. et al, Journal of Human Virology 3(5): 248 (Sept-Oct 2000)					
/K.C./	Kahan, B. & Camardo, J. (2001) <i>Transplantation</i> 72, 1181-1193.					
/K.C./	Kinter, A., Poli, G., Fox, L., Hardy, E. & Fauci, A. (1995) J. Immunol. 154, 2448-2459.					
/K.C./	Lane, B., Markovitz, D., Woodford, N., Rochford, R., Strieter, R. & Coffey, M. (1999) . <i>Immunol.</i> 163, 3653-3661.					
/K.C./	Terada N, et al., (1993) J of Cellular Phys., 154 pp 7-15.					
/K.C./	Ullman, K., Northrop, J., Verweij, C. & Crabtree, G. (1990) Annu. Rev. Immunol. 8, 421-452.					
/K.C./ /K.C./	Ward, S., Bacon, K. & Westick, J. (1998) <i>Immunity</i> 9, 1-11.					
/K.C./	Weissman, D., Dybul, M., Daucher, M., Davey, R., Walker, R. & Kovacs, J. (2000) J. Infect. Dis 181, 933-938.					
/K.C./	Willey, R., Smith, D., Lasky, L., Theodore, T., Earl, P., Moss, B., Capon, D. & Martin, M. (1988 <i>J. Virol.</i> 62, 139-147.					
/K.C./	Zella, D., Riva, A., Weichold, F., Reitz, M. & Gerna, G. (1998) Immunol. Lett. 62, 45-49.					
/K.C./	Roy, J., Sèbastien, J., Fortin, J. & Tremblay, M. (2002) Antimicrob. Agents Chemother. 46, 3447-3455.					
/K.C./	Sehgal, SN. (1998) Clin. Biochem. 31, 335-340.					
/K.C./	Simmons, G., Clapham, P., Picard, L., Offord, R. E., Rosenkilde, M. M., Schwartz, T. W., Buser R., Wells, T. N. & Proudfoot, A. E. (1997) <i>Science</i> 276, 276-279.					
/K.C./	Spina, C., Guatelli, J. & Richi	man, D. (1995) <i>J. Virol.</i> 69, 2977	7-2988.			
XAMINER			ATE CONSIDERED			
2 34 314111 AFM	/Kendra Carter/		05/06/2009			